Andrea B Apolo, M.D.
National Cancer Institute (NCI)
12
12
6
N/A
0
14
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+9 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (12)
Showing 10 of 12 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Anish Thomas, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Worked with same sponsors:
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Worked with same sponsors:
Yair Lotan, MD
University of Texas Southwestern Medical Center
Shared therapeutic areas:
Rahul Aggarwal, MD
University of California, San Francisco
Shared therapeutic areas:
Worked with same sponsors:
Malcolm J. Moore, MD
Princess Margaret Hospital, Canada
Shared therapeutic areas:
Worked with same sponsors:
Primo N. Lara, MD
University of California, Davis
Shared therapeutic areas:
Worked with same sponsors:
Dr. Sandy Srinivas
Stanford University
Shared therapeutic areas:
Lizhi Niu, PhD
Fuda Cancer Hospital
Shared therapeutic areas:
Shivaani Kummar, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Worked with same sponsors:
Lung-Ji Chang, PhD
Shenzhen Geno-Immune Medical Institute
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (12)
Showing 12 of 12 trials
Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)
Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma
Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies
Retrospective Review of FDG PET MRI Management of Patients With Muscle Invasive Bladder Cancer
Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
Cabozantinib for Advanced Urothelial Cancer
Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors
TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma
All 12 trials loaded